Spruce Biosciences, Inc. (traded on the Nasdaq Global Market under the ticker SPRB) officially completed its initial public offering (IPO) in October 2020. The clinical-stage biopharmaceutical enterprise priced its shares to trade publicly, raising capital to fund ongoing clinical trials and pipeline expansions targeting rare endocrine and neurological disorders.